Mipsagargin, a new plant-based prodrug is a new cancer drug that is claimed to offer favorable results in the treatment of cancer. It offers promising results and provides revolutionary treatment of cancer. Mipsagargin has been developed by Inspyr Therapeutics, Inc, and it can be used in place of chemotherapy in order to kill liver and brain cancers without leaving side effects as compared to other traditional cancer treatments.
It is a soluble, thapsigargin prodrug with has the cytotoxic analog of thapsigargin, 8-O-(12Aminododecanoyl)-8-O debutanoylthapsigargin (12-ADT) that is liked through a carboxyl group to the targeting peptide comprising of aspartic acid with potential antineoplastic activity.
Mipsagargin helps to prevent the supply of nutrition to tumor cells in order to inhibit the growth of a tumor.
Moreover, Mipsagargin is effective in avoiding systemic toxicity along with ensuring a higher concentration of the active agents at the location of a tumor.
This revolutionary drug has already been used in trials in order to analyze the treatment of Prostate Cancer, Prostatic Neoplasms, Advanced Solid Tumors, Hepatocellular Carcinoma, Glioblastoma Multiforme, to name a few.
After it is administered intravenously, Mipsagargin targets prostate specific membrane antigen (PSMA), a type II membrane carboxypeptidase. PSMA is overexpressed in prostate cancer cells and in the neovasculature of solid tumors.
With the help of hydrolysis, the drug is converted into the active cytotoxic analog of thapsigargin 12-ADT-Asp.
And it blocks the Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase (SERCA) pump to lead to an induction of apoptosis due to an increase in the concentration of cytosolic calcium. Mipsagargin is also an important component in the newly patented drug, MN-166 (ibudilast) used to treat Glioblastoma, a type of brain cancer.